GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » NonCurrent Deferred Liabilities

Tvardi Therapeutics (LTS:0HTC) NonCurrent Deferred Liabilities : £0.00 Mil (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Tvardi Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2025 was £0.00 Mil.

Tvardi Therapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Tvardi Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics NonCurrent Deferred Liabilities Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
NonCurrent Deferred Liabilities
- -

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
NonCurrent Deferred Liabilities - - - - -

Tvardi Therapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Tvardi Therapeutics Business Description

Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines